

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person *			2. Date of Event Requiring Statement (MM/DD/YYYY)		3. Issuer Name and Ticker or Trading Symbol		
Clem Kerry M			9/9/2021		ACORDA THERAPEUTICS INC [ACOR]		
(Last) (First) (Middle) 420 SAW MILL RIVER ROAD			4. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
			<input type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below) Chief Commercial Officer /				
(Street) ARDSLEY, NY 10502			5. If Amendment, Date Original Filed(MM/DD/YYYY)		6. Individual or Joint/Group Filing(Check Applicable Line)		
(City) (State) (Zip)			9/20/2021		<input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person		

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	11594 (1)	D	

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Employee Stock Option (right to buy)	(2)	3/15/2022	Common Stock	3000	\$158.10	D	
Employee Stock Option (right to buy)	(3)	3/6/2023	Common Stock	3543	\$182.76	D	
Employee Stock Option (right to buy)	(4)	3/5/2024	Common Stock	3543	\$236.28	D	
Employee Stock Option (right to buy)	(5)	3/4/2025	Common Stock	3188	\$214.44	D	
Employee Stock Option (right to buy)	(6)	3/2/2026	Common Stock	2159	\$213.18	D	
Employee Stock Option (right to buy)	(7)	3/1/2027	Common Stock	1250	\$164.85	D	
Employee Stock Option (right to buy)	(7)	3/1/2028	Common Stock	1967	\$146.10	D	
Employee Stock Option (right to buy)	(8)	3/8/2029	Common Stock	1834	\$81.06	D	
Employee Stock Option (right to buy)	(9)	11/7/2029	Common Stock	9168	\$14.46	D	

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Employee Stock Option (right to buy)	(10)	9/1/2030	Common Stock	2501	\$3.1572	D	

Explanation of Responses:

- (1) Includes 550 unvested restricted stock awards and 6,675 unvested restricted stock unit awards issued under the Issuer's 2015 Omnibus Incentive Compensation Plan. 275 of the restricted stock awards vest on December 1, 2021 and 275 vest on December 1, 2022, subject to continued service. The restricted stock units each represent a contingent right to one share of the Issuer's common stock, subject to continued service, vesting in installments of 20% and 40% on March 3, 2022 and September 3, 2022, respectively.
- (2) Options issued under the Issuer's 2006 Employee Incentive Plan. The shares subject to this option vested in installments and were fully vested on January 1, 2016.
- (3) Options issued under the Issuer's 2006 Employee Incentive Plan. The shares subject to this option vested in installments and were fully vested on January 1, 2017.
- (4) Options issued under the Issuer's 2006 Employee Incentive Plan. The shares subject to this option vested in installments and were fully vested on January 1, 2018.
- (5) Options issued under the Issuer's 2006 Employee Incentive Plan. The shares subject to this option vested in installments and were fully vested on January 1, 2019.
- (6) Options issued under the Issuer's 2015 Omnibus Incentive Compensation Plan. The shares subject to this option vested in installments and were fully vested on January 1, 2020.
- (7) Options issued under the Issuer's 2015 Omnibus Incentive Compensation Plan. The shares subject to this option vested in installments and were fully vested on January 1, 2021.
- (8) Options issued under the Issuer's 2015 Omnibus Incentive Compensation Plan. The shares subject to this option vest in equal quarterly installments over four years beginning on January 1, 2019, with the first quarterly installment vesting on April 1, 2019.
- (9) Options issued under the Issuer's 2015 Omnibus Incentive Compensation Plan. The shares subject to this option vest in equal quarterly installments over two years beginning on November 7, 2019, with the first quarterly installment vesting on February 7, 2020.
- (10) Options issued under the Issuer's 2015 Omnibus Incentive Compensation Plan. The shares subject to this option vest in equal quarterly installments over four years beginning on September 1, 2020, with the first quarterly installment vesting on December 1, 2020.

Remarks:

This amendment is refiled due to incorrect Power of Attorney on the initial Form 3 filing.

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Clem Kerry M 420 SAW MILL RIVER ROAD ARDSLEY, NY 10502			Chief Commercial Officer	

Signatures

/s/ Kerry M. Clem

9/20/2021

**Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

**LIMITED POWER OF ATTORNEY FOR
SECTION 16 REPORTING OBLIGATIONS**

Exhibit 24 - POWER OF ATTORNEY

For Executing Forms 3, 4 and 5

Know all by these presents, that the undersigned hereby constitutes and appoints each of Ron Cohen and Andrew Mayer or any of them acting singly, and with full power of substitution, the undersigned's true and lawful attorney-in-fact to:

1. prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the Securities and Exchange Commission (the "SEC"), a Form ID, including any amendments thereto, and any other documents necessary or appropriate to obtain codes and passwords enabling the undersigned to make electronic filings with the SEC of reports required by Section 16(a) of the Securities Exchange Act of 1934 or any rule or regulation of the SEC;
2. prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the SEC, Forms 3, 4 and 5, and any amendments thereto, in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;
3. do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4 or 5, complete and execute any amendment or amendments thereto, and file such form with the SEC and any stock exchange or similar authority; and
4. take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in his/her discretion.

The undersigned hereby grants to each attorney-in- fact full power and authority to do and perform all and every act and thing whatsoever requisite, necessary and proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or his/her substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is Acorda Therapeutics, Inc. assuming, any of the undersigned's responsibilities to comply with Section 16(a) of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by Acorda Therapeutics, Inc., unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 9 day of September 2021.

/s/ Kerry M. Clem

Kerry Clem

Notary Signature & Seal to be Placed Here:

Lim Kim A.
Notary Public, State of New York
No. 01L16144154
Qualified in Westchester County
Commission Expires Apr. 24, 2022